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Abstract
Setting: Kibong’oto National Tuberculosis Hospital (KNTH), Kilimanjaro, Tanzania.
Objective: Characterize the diagnostic process and interim treatment outcomes from patients treated for multidrug-
resistant tuberculosis (MDR-TB) in Tanzania.
Design: A retrospective cohort study was performed among all patients treated at KNTH for pulmonary MDR-TB between
November 2009 and September 2011.
Results: Sixty-one culture-positive MDR-TB patients initiated therapy, 60 (98%) with a prior history of TB treatment. Forty-
one (67%) were male and 9 (14%) were HIV infected with a mean CD4 count of 424 (6106) cells/ml. The median time from
specimen collection to MDR-TB diagnosis and from diagnosis to initiation of MDR-TB treatment was 138 days (IQR 101–159)
and 131 days (IQR 32–233), respectively. Following treatment initiation four (7%) patients died (all HIV negative), 3 (5%)
defaulted, and the remaining 54 (89%) completed the intensive phase. Most adverse drug reactions were mild to moderate
and did not require discontinuation of treatment. Median time to culture conversion was 2 months (IQR 1–3) and did not
vary by HIV status. In 28 isolates available for additional second-line drug susceptibility testing, fluoroquinolone,
aminoglycoside and para-aminosalicylic acid resistance was rare yet ethionamide resistance was present in 9 (32%).
Conclusion: The majority of MDR-TB patients from this cohort had survived a prolonged referral process, had multiple
episodes of prior TB treatment, but did not have advanced AIDS and converted to culture negative early while completing
an intensive inpatient regimen without serious adverse event. Further study is required to determine the clinical impact of
second-line drug susceptibility testing and the feasibility of alternatives to prolonged hospitalization.
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Background
Multidrug-resistant tuberculosis (MDR-TB), defined as resis-
tance to both isoniazid and rifampin, remains poorly diagnosed
and treated [1]. Of the 440,000 estimated incident cases annually
in 2008, only 7% were reported to the World Health Organization
(WHO) [2] and of those, only a fifth were treated according to
recommended guidelines [1]. Treatment outcomes are inferior to
drug-susceptible TB in part because medications used in the
treatment of MDR-TB are less potent and associated with a
greater number of side effects, and duration is recommended to
last at least 20 months which can compromise adherence [3,4].
The second-line drugs used in the treatment of MDR-TB have
only recently been available in many TB endemic countries
following WHO rollout initiatives. Analysis of outcomes from
diverse settings with recent access to MDR-TB treatment is
therefore critical for study of comparative efficacy and for design
of similar programs in other emerging locations.
Tanzania is a WHO designated high burden TB country [2].
Although data on drug-resistance are limited, a recent cluster
survey placed the prevalence from MDR-TB among retreatment
cases at only 3.9% [5]. Treatment for MDR-TB was made
available in 2009 and the Ministry of Health selected Kibong’oto
National Tuberculosis Hospital (KNTH) in the Kilimanjaro
region of Northern Tanzania as the initial referral hospital for
all MDR-TB cases [6]. Treatment consisted of a standardized
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e62034
MDR-TB regimen based only on drug susceptibility results for the
first-line medications isoniazid, rifampin, streptomycin and eth-
ambutol. Therefore, MDR-TB in Tanzania reflects a unique
population with little to no exposure to second-line medications
and with a relatively low background prevalence of drug resistance
that may lend to favorable outcomes if patients are treated with a
standardized MDR-TB regimen.
However, given that long-term outcomes such as relapse
following treatment of MDR-TB can take years to determine,
correlative intermediate markers have been used. The most
studied marker in pulmonary TB has been sputum culture
conversion from positive to negative [7–9] and MDR-TB patients
that fail to convert their sputum by two months are less likely to
achieve cure [10]. Therefore, the following study describes the
diagnostic referral process, clinical presentation and interim
treatment outcomes including the duration of sputum culture
conversion from the first cohort of patients treated for MDR-TB in
Tanzania. Furthermore, among the available pretreatment M.
tuberculosis isolates, drug-susceptibility testing was performed to
determine the range of resistance to drugs within the standardized




KNTH hospital staff reviewed consecutive medical charts from
patients referred for MDR-TB treatment from November 2009 to
September 2011. Patients were considered eligible for inclusion if
they had a Mycobacterium tuberculosis isolate with resistance to
isoniazid and rifampin and had been started on a MDR-TB
regimen. The institutional review board at Kilimanjaro Christian
Medical Center (KCMC) and the University of Virginia approved
this study.
Study Site
KNTH was a former sanatorium, and is currently the country’s
only referral hospital for MDR-TB management with a dedicated
40-bed capacity in addition to separate facilities for treatment of
drug-susceptible TB. Forty kilometers from KNTH, the biotech-
nology laboratory affiliated with the Kilimanjaro Clinical
Research Institute performs smear microscopy, mycobacterial
culture and first-line susceptibility testing by Bactec MGIT (BD,
Franklin Lakes, USA), and DNA probe forMycobacterium tuberculosis
complex (Gen-Probe, San Diego, USA). The laboratory has
completed external proficiency testing. Second-line medication
minimum inhibitory concentrations (MICs) on MYCOTB Sensi-
titre plates (TREK Diagnostics, Cleveland, USA) have only
recently been available and as such, the MICs reported were
performed on archived pretreatment isolates and not available for
therapeutic decisions in this initial cohort. Repeat DNA probe and
sequencing of non-tuberculous mycobacteria was later performed
at the University of Virginia. For study inclusion, only the initial
susceptibility performed at the national TB reference laboratory in
Dar es Salaam was utilized.
MDR-TB Referral and Treatment Program
A MDR-TB suspect’s specimens were transported to the
national TB reference laboratory based on a series of mechanisms
including routine clinical practice/physician suspicion, drug-
resistance surveillance, and independent research [11]. The
national TB reference laboratory performed mycobacterial
culture, biochemical speciation and first-line susceptibility testing
by proportion method on Lowenstein-Jensen slants.
Culture positive MDR-TB patients were treated at KNTH with
a standardized regimen during the inpatient intensive phase with
one injectable agent (kanamycin or pending stock availability,
amikacin or capreomycin), a fluoroquinolone (levofloxacin or
pending stock availability, ofloxacin), ethambutol (if susceptible),
pyrazinamide, ethionamide and cycloserine. Drugs were directly
administered seven days per week and dosed by weight [11]. In
case of severe adverse event, the dosage was modified or the drug
substituted. Para-aminosalicylic acid (PAS) was available for those
requiring substitution. The inpatient regimen was continued for at
least 4 months following culture conversion, defined as two
consecutive negative cultures at least one month apart, and a
minimum of 6 months. Then if symptomatically improved,
subjects were eligible for discharge to complete an additional 18
months of a continuation phase that did not include the injectable
agent. Every patient was tested for HIV and antiretroviral therapy
(ART) was initiated, if indicated, within 8 weeks of MDR-TB
treatment initiation [11]. ART regimens were either (1) stavudine
or zidovudine plus lamivudine plus efavirenz or nevirapine, or (2)
tenofovir plus emtricitabine plus efavirenz.
Prior to treatment initiation, sputum was collected for smear
microscopy and culture on Lowenstein-Jensen solid agar, and
monthly thereafter until the end of intensive phase. Clinical
examination was performed daily and laboratory parameters
including hematology and a comprehensive metabolic panel were
monitored monthly. Chest radiographs were taken prior to
treatment initiation and at 6 months per KNTH protocol.
Definitions and Outcome Measures
For purposes of analysis, adverse events were categorized as
mild if an asymptomatic laboratory parameter change necessitated
clinical observation only; moderate if minimal or non-invasive
intervention was indicated but without alteration to the MDR-TB
drug regimen; or severe if medically significant and treatment
alteration was necessary [12]. For comparison of pretreatment and
6 month chest radiographs, the extent of affected lung was
determined by zonal score and reported as percentage of the total
lung [13]. Weight (kg) was recorded pretreatment and at 6
months. Treatment outcomes were determined following the
inpatient phase of therapy, and death was categorized as occurring
by any cause; default, if treatment was interrupted for greater than
one week; and intensive phase complete; if the injectable agent was
discontinued and the patient discharged on an oral continuation
phase regimen. KNTH staff traced defaulters and if treatment was
resumed with ,2 months interruption, then the subject was
eligible for inclusion in analysis of intensive phase completion.
All statistical tests were two-tailed with a p-value ,0.05
considered significant. Results were expressed as simple propor-
tions with mean (95% Confidence Interval) or median (inter-
quartile range) when appropriate. Means were compared by
paired t-test and medians with the Mann Whitney U test for non-
parametric data.
Results
Demographics and Clinical Characteristics
A total of 70 patients were referred to KNTH from November
2009 through September 2011 for MDR-TB treatment (Figure 1).
Sixty-one (87%) patients were referred based on routine clinical
practice/physician suspicion, while the remainder by drug-
resistance surveillance or independent research, including 8
(12%) for whom initial screening susceptibility was made by
molecular detection of drug-resistant mutations for isoniazid and
rifampin (MTBDRplus, Hain Lifescience, Nehren, Germany). For
MDR-TB Diagnosis and Treatment in Tanzania
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two patients initial drug susceptibility testing results could not be
confirmed and another 3 patients were found to have a M.
tuberculosis isolate which was sensitive to isoniazid or rifampin, and
thus excluded from the analysis. Four patients were further
excluded as their isolate was later identified as non-tuberculous
mycobacteria (NTM) including two patients with M. fortuitum, and
one each with M. abscessus and M. avium complex (Figure 1).
Thus, 61 patients were included in the analysis and all had
pulmonary TB with only one additionally having an extrapulmo-
nary focus. Forty-two (69%) were from Dar es Salaam but the
remainder of patients represented diverse geographic locations in
the country (Table 1). The average age was 36 years (613), and 41
(67%) were male. Nine (14%) had HIV with a mean CD4+
lymphocyte count of 424 cells/ml (range 317 - 530). Six (67%) of
the nine patients with HIV were on ART prior to MDR-TB
treatment. Diabetes mellitus was rare and found in only 2 (3%).
Sixty patients (98%) had a prior history of TB of which 52 (87%)
had two or more episodes of the infection in the past. Forty-five
(75%) had an unfavorable outcome during the last episode that
resulted in drug-susceptibility testing and the diagnosis of MDR-
TB. The median time between sputum specimen collection and
diagnosis of MDR-TB was 138 days (IQR 101–159). The median
time from diagnosis of MDR-TB to initiation of MDR-TB
treatment regimen was 131 days (IQR 32–233).
Treatment Regimens and Adverse Events
All patients received the standardized MDR-TB treatment
regimen. Ethambutol resistance was present in 43 (71%). Twenty-
one (34%) of patients had a medication changed during treatment;
17 changes (81%) were due to stock shortage, while 4 (19%) were
because of a severe adverse event (all with nephrotoxicity). Liver
function remained within acceptable range for all patients and no
serious hepatoxicity was noted. Three patients developed psychosis
that resolved following temporary discontinuation of cycloserine
and treatment with antipsychotic agents. Of the 61 patients, 49
(80%) experienced mild or moderate adverse events potentially
related to medication (Figure 2). Of the 9 HIV infected patients,
only 1 (11%) developed a severe adverse event (nephrotoxicity),
but the remaining 8 had at least one mild or moderate adverse
event.
Interim Treatment Outcomes
Fifty-four (89%) patients completed the intensive phase and
were discharged on an oral continuation regimen (Table 2). The
median duration of the intensive phase was 7 months (IQR 6–8).
Among HIV infected patients, 8 (89%) completed the intensive
phase which did not differ from the HIV uninfected patients. A
total of 4 patients (8%) died, all during the first month of
treatment, and none had HIV (Table 2). An additional three
patients (5%) defaulted and upon tracing one had died, one was
restarted on MDR-TB therapy following 3 months of interruption,
and the other was lost to follow-up. With regard to the time
required for sputum culture conversion, 8 (13%) patients had
missing data and could not be included. Thus of the remaining 46
(85%), the median time to sputum culture conversion was 2
months (IQR 1–3) and did not differ by HIV status (p = 0.8).
Nevertheless, 18 (39%) patients required $3 months for sputum
culture conversion, with a maximum of 8 months (Figure 3).
Cavitary disease was present in 22 (36%) of the 48 patients for
whom a pretreatment chest radiograph was available for analysis.
Overall, patients had a significant cumulative improvement in the
percent of damaged lung at the 6-month chest radiograph (HIV
uninfected with mean improvement of 20% and estimated residual
involvement of 37%, 95% CI 30–44%, p,0.001; and HIV
infected with mean improvement of 14% and 32% residual, 95%
CI 12–53%, p= 0.004). A significant increase was also observed in
weight (HIV uninfected with mean gain of 5.9 kg and 6 month
mean of 58.7 kg, 95% CI 55.3–62.1 kg, p,0.001; and HIV
infected with mean gain of 6.2 kg and 6 month mean of 59.1 kg,
95% CI 46.2–72.0 kg, p= 0.009).
Pretreatment M. tuberculosis isolates were later recovered from
only 28 (46%) patients for MIC testing to the second-line drugs
within the MDR-TB treatment regimen. 15 patients with
recovered isolates had culture converted $3 months and it was
observed that 2 (13%) patients had isolates with high MIC to
ofloxacin and kanamycin predictive of in vitro resistance and 6
(40%) had MICs predictive of resistance to ethionamide (Table 3).
In contrast, all isolates had low MICs to PAS. None of the 4
patients that died had isolates recovered.
Discussion
This work describes the first cohort of patients treated for
MDR-TB in Tanzania. Most were able to complete the intensive
phase of inpatient therapy. Nearly all experienced medication
related events, but few were severe or requiring of regimen
alteration. While sputum culture conversion was delayed up to 8
months for some patients, the median duration fell within expected
norms from other recent cohorts [7,10].
There is a paucity of published data from MDR-TB treatment
programs in Africa. However in comparison to the reports of
integrated HIV/MDR-TB treatment programs from South Africa
[7,14,15] we found a similarly high rate of sputum culture
conversion among the subjects referred for MDR-TB treatment in
Tanzania. Comprehensive programs from Lesotho have demon-
strated that outcomes among HIV/MDR-TB patients can
approach those of HIV uninfected patients [16] and this study
provides further evidence of that possibility, albeit among a HIV
infected cohort without profound immunosuppression. Despite a
HIV prevalence of 14%, which is lower than the expected
proportion among TB patients in Tanzania, all HIV infected
subjects included in this study had CD4 counts .300 cells/ml at
the time of MDR-TB treatment initiation and two-thirds were on
ART prior to presentation. In addition, the vast majority of all
patients had two or more prior episodes of TB, thus it is suspected
that the entire study population was enriched for those with drug
resistance acquired on therapy that were relatively healthy enough
to survive the prolonged referral process prior to treatment. This
Figure 1. Patients referred to KNTH for MDR-TB treatment.
KNTH= Kibong’oto National TB Hospital, Tanzania. MDR-TB= multi-
drug-resistant tuberculosis. All patients had pulmonary TB.
doi:10.1371/journal.pone.0062034.g001
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has not been the case from South Africa where transmitted drug-
resistant strains are thought to fuel the epidemic [15]. Yet in
general, studies from southern Africa acknowledge a similar
survival bias of subjects referred for treatment initiation [7], and
not until widespread efforts at intensified case finding with rapid
diagnostics for drug-resistance are implemented can we assess the
true efficacy of the MDR treatment program in a given region.
We remain encouraged that the cumulative increase in weight
and radiographic resolution in our cohort are further suggestive of
ultimate treatment success [17]. Indeed, in comparison to those
completing therapy, patients that died had a trend toward more
extensive lung disease. Pretreatment isolates were not recovered
from the patients that died for second-line susceptibility testing,
although it is of additional concern that resistance to key
medications such as fluoroquinolones or aminoglycosides may
have contributed to the unfavorable clinical response. We chose to
perform MIC testing because the commercial 96-well MIC plate
was relatively straightforward to deploy compared to the
cumbersome agar proportion methodology. Of the second-line
MIC testing performed on the available isolates, resistance to
ofloxacin and kanamycin was rare but not absent and a worrisome
trend of the highest MICs was observed in patients with delayed
culture conversion. As has been observed, MICs were lower for
moxifloxacin compared to ofloxacin, as well as for amikacin
compared to kanamycin [18]. We have previously noted low
plasma concentrations of anti-TB medications at KNTH, there-
fore it stands to reason that optimization of pharmacokinetics
within a class may further improve outcome [19]. In addition, of
the oral second-line agents, PAS appeared more reliably
susceptible than ethionamide. While the use of MICs in lieu of
the standard qualitative susceptibility methods requires further
study, in our view there exists appeal in examining the use of MICs
for regimen individualization.
Table 1. Baseline characteristics for those initiating MDR-TB treatment (N= 61).
Characteristic Subcategory Number
Age, mean years (6SD) N/A 36 (13)
Gender (%N) Male 41 (67)
Female 20 (33)
Cigarette smoking (%N) Yes 16 (26)
No 21 (34)
Unknown 24 (39)
Alcohol use (%N) Yes 9 (15)
No 29 (47)
Unknown 23 (38)






History of previous TB (%N) Yes 60 (98)
No 1 (2)
Number of prior TB episodes (% with previous TB) One 8 (13)
Two 29 (48)
Three 12 (20)
Four or more 11 (18)
Outcome of last TB episode (% with previous TB) Favorable 15 (25)
Unfavorable 45 (75)
Time from specimen collection to MDR-TB diagnosis, median days (IQR) N/A 138 (101–159)
HIV status (%N) Positive* 9 (15)
Negative 52 (85)
CD4 cells/ml, mean (6SD) among HIV positive N/A 424 (106)
Diabetes (%N) Yes 2 (3)
No 59 (97)
Cavitary disease{ Yes 22 (46)
No 26 (54)
N/A= not applicable.
*6 (67%) of HIV positive patients were on antiretroviral therapy prior to referral for MDR-TB treatment.
{Forty-eight baseline chest radiographs were available for analysis.
doi:10.1371/journal.pone.0062034.t001
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Other MDR-TB cohorts have reported a larger number of
patients stopping medication due to severe adverse events,
described in up to 55% of all subjects and even death related to
hepatic failure [20–23]. Our rates were lower, which we suspect
was biased by survival to referral in a population with considerable
prior exposure and tolerance to first-line anti-tuberculous medi-
cations including pyrazinamide. While our analysis was restricted
to the inpatient intensive phase, common side effects included
arthralgia and headache, which may be difficult to ascribe to
medication alone, though certainly pyrazinamide may cause
arthralgia in the setting of urate arthropathy [24]. 20% of patients
experienced peripheral neuropathy likely due to ethionamide,
cycloserine or the additive combination. A more aggressive
strategy of pyridoxine supplementation may therefore be of
benefit.
Fortunately, aminoglycoside related nephrotoxicity and ototox-
icity were uncommon despite monthly monitoring. Notably
however, cycloserine related psychosis was morbid when observed,
necessitating temporary drug discontinuation and antipsychotic
treatment. Patients with this complication were HIV negative and
therefore not on efavirenz, which has been previously suggested as
additive to psychiatric side effects [25]. Terizidone, a derivative of
cycloserine, may be less toxic and is a preferred alternative in
similar treatment programs [26]. Medication toxicity notwith-
standing, a significant proportion of subjects had treatment change
due to periodic stock shortage. Reliable procurement is a realistic
obstacle that must be considered for similar resource-limited
settings planning MDR-TB treatment and we recommend as
becoming integral to staff and facility training.
There are several limitations to this study, largely implicit to
retrospective analysis. Further detail about medication change or
interventions to ameliorate side effects or assure adherence were
unavailable. As discussed, the relative homogeneity of the
population may also limit generalizability. The favorable interim
outcomes from this initial cohort may be dampened as rapid
diagnostics for MDR-TB are more widely available in Tanzania,
which will likely identify sicker patients that previously would not
have survived to referral. Lastly, lack of routine second-line
susceptibility testing did not allow for determination of flouroqui-
nolone or injectable agent resistance in all patients and hence the
proportion that may have harbored extensively drug-resistant TB
and the contribution of such resistance to treatment outcome is
unknown.
Of further cautionary note, we found non-tuberculous myco-
bacteria typically resistant to certain TB medication that may
otherwise have been misclassified as MDR-TB without confirma-
tory speciation. Additionally, the isoniazid and rifampicin mono-
resistance detected would greatly alter the treatment regimen.
Thus, this study reinforces the need for laboratory capacity beyond
testing for rpoB mutation to exist alongside any new MDR-TB
program.
In summary, the majority of patients within the first cohort
treated for MDR-TB in Tanzania completed an intensive phase of
inpatient therapy without serious adverse events. Patients had a
prior history of TB treatment, likely acquired drug-resistance, did
not have significant immunosuppression and were relatively
healthy enough to have survived a prolonged referral process.
Countries with similar infrastructure that are entertaining start of a
centralized MDR-TB program might anticipate similar findings,
yet further follow-up of the long-term outcomes remains.
Additional setting-specific study can determine the clinical impact
of quantitative susceptibility testing for medications within the
MDR-TB regimen, and the feasibility of alternatives to prolonged
hospitalization. As efforts are underway to scale-up MDR-TB
diagnosis for other locations in Tanzania, such studies are urgently
needed.
Figure 2. Prevalence of medication related symptoms. The prevalence of medication related symptoms during the inpatient intensive phase
occurring at least once in an individual patient, as determined by percentage of total patients (N = 61).
doi:10.1371/journal.pone.0062034.g002
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Figure 3. Distribution of the time to sputum culture conversion. Legend: Sputum was collected for culture prior to treatment initiation and
monthly thereafter. Culture conversion was defined as the first of two consecutive months of negative cultures. Eight subjects were excluded as
regular follow-up culture results were unavailable.
doi:10.1371/journal.pone.0062034.g003
Table 2. Comparison of patients that completed intensive phase of MDR-TB therapy to those that died.
Characteristic Intensive phase complete, N=54* Died, N=4 p-value
Age, mean years (SD) 35 (13) 31(13) 0.43
Gender, male (%N) 36 (67) 3(75) 0.6
HIV infected (%N) 8 (15) 0 0.4
Mean number of prior TB treatment episodes (SD) 2.5 (1.1) 3.5 (1.3) 0.08
Unfavorable treatment outcome of the last episode (%N) 41 (76) 3 (75) 0.69
Median time between MDR-TB diagnosis and treatment, days
(minimum-maximum)
272 (26–888) 255 (193–317) 0.8
Mean percent of lung destruction (SD) 53 (23) 86 (11.7) 0.05
Median duration of intensive phase, months (IQR) 7 (6–8) n/a n/a
Median time to culture conversion, months (IQR){ 2 (1–3) n/a n/a
*Excludes 3 patients that defaulted.
{Excludes 8 patients for whom follow-up sputum culture results unavailable.
N/a = not applicable.
doi:10.1371/journal.pone.0062034.t002
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Table 3. Additional second-line susceptibility testing of recovered isolates.
Drug MIC mg/ml (IQR) Total, N=28 Conversion ,3 mo., N=13 Conversion $3 mo., N=15
Resistant (%N) Resistant (%N) Resistant (%N)
Ofloxacin 0.5 (IQR 0.5–1.0) 3 (11) 1 (8) 2 (13)
Moxifloxacin 0.12 (IQR 0.06–0.25) 4 (14) 1 (8) 1 (7)
Amikacin 0.25 (IQR 0.25–0.5) 1 (4) 0 1 (7)
Kanamycin 1.2 (IQR 1.2–2.5) 3 (11) 1 (8) 2 (13)
Ethionamide 2.5 (IQR 1.2–5.0) 9 (32) 3 (23) 6 (40)
PAS #0.5 (IQR 0) (min #0.5-max 1.0) 0 0 0
Cycloserine* 8.0 (IQR 8.0–16.0) n/a n/a n/a
Pyrazinamide susceptibility was not performed. PAS =para-aminosalicylic acid. Conversion = time to sputum culture conversion to negative in months (mo). Resistance
determined by minimum inhibitory concentration (MIC) analysis on MYCOTB Sensititre plates (TREK Diagnostics) with the following resistance breakpoints (ofloxacin
2.0 mg/ml; moxifloxacin 0.25 mg/ml; amikacin 1.0 mg/ml, kanamycin 5.0 mg/ml, ethionamide 5.0 mg/ml; PAS 2.0 mg/ml)[21;27].
*Resistance correlation with MIC in liquid media is not well established for cycloserine. One subject with culture conversion $3 months was resistant to both ofloxacin
and kanamycin, considered extensively drug-resistant (XDR-TB).
doi:10.1371/journal.pone.0062034.t003
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